Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02294357 | Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib | terminated | Phase 2 | 45 | OncotherapeuticsINDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
| NCT03733691 | Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | terminated | Phase 2 | 19 | OncotherapeuticsINDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT04843579 |
| Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients(ClaSPd) |
| terminated |
| Phase 2 |
| 4 |
| Weill Medical College of Cornell UniversityOTHER |
| 1 |
| Oct 25, 2023 |
| clinicaltrials |
| NCT01177683 | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma | terminated | Phase 1 / Phase 2 | 32 | Sherif Farag, MB, BSOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT04205240 | Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma | terminated | Phase 2 | 1 | Srinivas DevarakondaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03201250 | Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | University of NebraskaOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT02906332 | Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) | terminated | Phase 2 | 12 | Hackensack Meridian HealthOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT04119336 | Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma | terminated | Phase 2 | 2 | Andrew Yee, MDOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT02794246 | CART-19 Post-ASCT for Multiple Myeloma | terminated | Phase 2 | 6 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03782064 | Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma | terminated | Phase 2 | 5 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03411031 | Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide | terminated | Phase 2 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04635735 | Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT03639610 | PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function(BRIDGE) | terminated | Phase 2 | 35 | Oncopeptides ABINDUSTRY | 3 | Mar 10, 2023 | clinicaltrials |
| NCT02807454 | A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma(FUSIONMM-003) | terminated | Phase 2 | 37 | CelgeneINDUSTRY | 9 | Feb 21, 2023 | clinicaltrials |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 46 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT01838369 | A Phase II Study of BI-505 in Smoldering Multiple Myeloma | terminated | Phase 2 | 4 | BioInvent International ABINDUSTRY | 1 | Jan 11, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT03481556 | Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM(ANCHOR) | terminated | Phase 1 / Phase 2 | 56 | Oncopeptides ABINDUSTRY | 4 | Dec 19, 2022 | clinicaltrials |
| NCT01881789 | Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 22 | AmgenINDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT01416428 | Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 210 | AmgenINDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT01464034 | A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 136 | Criterium, Inc.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT00464178 | A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 7 | Hackensack Meridian HealthOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT01555281 | Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma | terminated | Phase 1 / Phase 2 | 33 | Swiss Cancer InstituteOTHER | 2 | Jul 7, 2022 | clinicaltrials |
| NCT03256045 | Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 9 | University of WashingtonOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT03303950 | Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis | terminated | Phase 2 | 6 | University of UtahOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT03850522 | PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma | terminated | Phase 2 | 6 | Lene Meldgaard KnudsenOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT03104270 | Combination Study for High Risk Multiple Myeloma Patients | terminated | Phase 2 | 13 | OncotherapeuticsINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT00792506 | Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 1 | ItalfarmacoINDUSTRY | 1 | Feb 2, 2022 | clinicaltrials |
| NCT03875495 | A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) | terminated | Phase 1 / Phase 2 | 9 | Genenta ScienceINDUSTRY | 1 | Jan 28, 2022 | clinicaltrials |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | terminated | Phase 1 / Phase 2 | 8 | AGC Biologics S.p.A.INDUSTRY | 2 | Jan 19, 2022 | clinicaltrials |
| NCT01045382 | MSC and HSC Coinfusion in Mismatched Minitransplants | terminated | Phase 2 | 39 | University of LiegeOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT01101594 | A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 17 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT03634800 | Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)(RISE-M) | terminated | Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT01946152 | Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT00445068 | Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma | terminated | Phase 2 | 38 | Novartis PharmaceuticalsINDUSTRY | 2 | Jul 14, 2021 | clinicaltrials |
| NCT03567616 | A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 8 | AbbVieINDUSTRY | 3 | Jun 30, 2021 | clinicaltrials |
| NCT02128230 | UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | terminated | Phase 2 | 20 | University of ArkansasOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT02757326 | ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma(ABC-103) | terminated | Phase 1 / Phase 2 | 13 | RedHill Biopharma LimitedINDUSTRY | 1 | Jun 18, 2021 | clinicaltrials |
| NCT03687125 | Tinostamustine Conditioning and Autologous Stem Cell(TITANIUM1) | terminated | Phase 1 / Phase 2 | 6 | Mundipharma-EDO GmbHINDUSTRY | 3 | Jun 18, 2021 | clinicaltrials |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | terminated | Phase 2 / Phase 3 | 40 | Kiadis PharmaINDUSTRY | 7 | Jun 14, 2021 | clinicaltrials |
| NCT03520985 | Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma(OptiPOM) | terminated | Phase 2 | 34 | Swiss Cancer InstituteOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT00003511 | Antineoplaston Therapy in Treating Patients With Multiple Myeloma | terminated | Phase 2 | 5 | Burzynski Research InstituteOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT03910439 | Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | May 12, 2021 | clinicaltrials |
| NCT03340883 | Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 21 | Chinook Therapeutics, Inc.INDUSTRY | 1 | Apr 1, 2021 | clinicaltrials |
| NCT00437034 | Aflibercept for Relapsed Multiple Myeloma | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2021 | clinicaltrials |
| NCT03512353 | A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers | terminated | Phase 2 | 7 | AmgenINDUSTRY | 1 | Jan 8, 2021 | clinicaltrials |
| NCT01121120 | Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients(TXA127-PBSC) | terminated | Phase 2 | 75 | Tarix PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03117361 | Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide | terminated | Phase 2 | 10 | PharmaMarINDUSTRY | 3 | Dec 2, 2020 | clinicaltrials |
| NCT02897830 | Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma(IFM2014-03) | terminated | Phase 2 | 46 | University Hospital, ToulouseOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT03033316 | A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma(AMETHYST) | terminated | Phase 1 / Phase 2 | 7 | Enceladus Pharmaceuticals BVINDUSTRY | 0 | Nov 6, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Nov 1, 2023source: clinicaltrials